A study of analyst recommendations at the major brokerages shows that Pitney Bowes Inc (PBI - Get Report) is the #73 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period. In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the list of stocks with strong buyback activity was ranked according to those averages.Investors are often keenly interested in knowing which companies are buying back their own stock, because companies often will only make such a move if they feel their stock is undervalued. Pitney Bowes Inc is a company with strong buyback activity that is also considered a compelling buy by analysts; a bullish investor could take this to mean that sharp analyst minds came to the same bullish conclusion as the company itself that the stock is a good value, and therefore the stock should do well in the future. Analysts studying companies buying back their own stock will also factor into their analysis that future earnings will now be spread over a smaller share count, thereby increasing the per-share earnings the remaining shares will enjoy, versus what that same number would have been absent the stock buyback activity. According to the ETF Finder at ETF Channel, PBI makes up 1.69% of the WisdomTree U.S. SmallCap Quality Dividend Growth Fund ETF (DGRS) which is trading lower by about 0.6% on the day Friday. PBI operates in the Office Supplies sector, among companies like MSA Safety Inc (MSA) which is up about 0.4% today, and Herman Miller Inc. (MLHR) trading lower by about 0.5%. Below is a three month price history chart comparing the stock performance of PBI, versus MSA and MLHR. PBI is currently trading down about 0.4% midday Friday.
More from Stocks
PG&E Warns of Potential Major Power Shut Off on Wednesday
Wind storm could trigger a public safety power shutoff for a portion of homes and businesses in the Sierra Foothills, North Valley and North Bay.
Novartis Still a Buy Despite Controversy Over Blockbuster Drug
Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact on the company's bottom line," Cramer told members of his Action Alerts PLUS club for investors during an exclusive video-conference call.
Could Netflix Survive on Just Its Own Original Content?
Netflix says that viewers shell out for original shows like Stranger Things and Orange is the New Black -- but production costs have ballooned roughly 30% since last year, which has many investors spooked.
Jim Cramer: Mastercard Is One Thing Money Can Buy
The slogan was: There are some things money can't buy; for everything else, there's Mastercard. Fast forward more than two decades and the world of fintech and digital payment processing has changed, and Mastercard has changed right along with it.